Discovery and optimization of 3-(4-aryl/heteroarylsulfonyl)piperazin-1-yl)-6-(piperidin-1-yl)pyridazines as novel, CNS penetrant pan-muscarinic antagonists.

Bender AM, Weiner RL, Luscombe VB, Ajmera S, Cho HP, Chang S, Zhan X, Rodriguez AL, Niswender CM, Engers DW, Bridges TM, Conn PJ, Lindsley CW
Bioorg Med Chem Lett. 2017 27 (15): 3576-3581

PMID: 28633897 · PMCID: PMC6659418 · DOI:10.1016/j.bmcl.2017.05.042

This letter describes the synthesis and structure activity relationship (SAR) studies of structurally novel M antagonists, based on a 3-(4-aryl/heteroarylsulfonyl)piperazin-1-yl)-6-(piperidin-1-yl)pyridazine core, identified from a high-throughput screening campaign. A multi-dimensional optimization effort enhanced potency at human M (hM ICs<200nM), with only moderate species differences noted, and with enantioselective inhibition. Moreover, CNS penetration proved attractive for this series (rat brain:plasma K=2.1, K=1.1). Despite the absence of the prototypical mAChR antagonist basic or quaternary amine moiety, this series displayed pan-muscarinic antagonist activity across M (with 9- to 16-fold functional selectivity at best). This series further expands the chemical diversity of mAChR antagonists.

Copyright © 2017 Elsevier Ltd. All rights reserved.

MeSH Terms (12)

Animals Brain CHO Cells Cricetulus Humans Muscarinic Antagonists Piperazine Piperazines Pyridazines Rats Receptor, Muscarinic M4 Structure-Activity Relationship

Connections (1)

This publication is referenced by other Labnodes entities: